Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Seattle, is making strides in developing medicines that address unmet medical needs in the field of oncology. The company's flagship program is centered around Endoxifen, an active metabolite of tamoxifen, which is undergoing Phase II clinical trials to treat and avert breast cancer. Atossa is also currently developing AT-H201, a promising treatment for lung injury brought on by cancer treatment. To further bolster its research capabilities, Atossa has entered into a research agreement with the Dana-Farber Cancer Institute, with a specific focus on cytokine-coated nanoparticles that hold promise in the treatment of breast cancer. Founded in 2008 as Atossa Genetics Inc., the company rebranded as Atossa Therapeutics, Inc. in January 2020, prioritizing its mission to deliver groundbreaking solutions to cancer patients in need.
Atossa Therapeutics, Inc.'s ticker is ATOS
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 1-10 employees working at Atossa Therapeutics, Inc.
It is https://atossatherapeutics.com/
Atossa Therapeutics, Inc. is in the Healthcare sector
Atossa Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Atossa Therapeutics, Inc.'s industry peers: